Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWN110 in Healthy Participants and Overweight or Obese Participants
NCT07779980Phase 1Not yet recruiting
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MWN110 in obesity (3 arms), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoints: Treatment-Emergent Adverse Events, Number of participants with abnormal vital signs and 4 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
MWN110
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07779980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07779980.